Cello Health PLC Appointment of Executive Director (5960C)

TIDMCLL

RNS Number : 5960C

Cello Health PLC

02 October 2018

2 October 2018

Cello Health plc

("Cello", the "Company", or the "Group")

Appointment of Executive Director

Further to the announcement of the Interim Results on 19 September 2018, Cello Health plc (AIM: CLL), the global healthcare-focused advisory Group, is pleased to announce that Julia Ralston has been appointed Executive Director of the Company with immediate effect, bringing the executive team to a total of four. Julia's presence on the Board will ensure appropriate levels of governance and control around Cello's expanding US business.

Julia is CEO of Cello Health in the US, having joined the Group as CEO of MedErgy in 2011 following its acquisition by Cello. Julia is responsible for Cello's strategic growth in the US and facilitating collaboration in the region across the Group's capabilities in consulting, insight, and communications.

Enquiries:

 
 Cello Health plc                        020 7812 8460 
 Mark Scott, Chief Executive 
 Mark Bentley, Group Finance Director 
 
 Cenkos Securities plc                   020 7397 8900 
 Mark Connelly 
 Harry Hargreaves 
 
 Buchanan                                020 7466 5000 
 Mark Court 
 Jamie Hooper 
 Sophie Wills

About Cello Health plc

Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

Cello Health plc enables clients to commercialise and differentiate their assets and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.

For further information, please visit: https://cellohealthplc.com

Regulatory information

 
 Full name (age)      Current directorships:         Previous directorships 
                                                      / partnerships (over 
                                                      the last five years): 
 Julia Anne Ralston   Cello Health Inc.              None 
  (61)                 Cello Health BioConsulting 
                       Inc. 
                       Cello Health Consulting 
                       Inc. 
                       Defined Health Inc. 
                       Worldwide Promedica 
                       Inc. 
                       Insight Research Group 
                       US Inc 
                       Cello Health Advantage 
                       Inc 
                       MedErgy HealthGroup 
                       Inc 
                       Cello Health Communications 
                       Inc 
                       MedErgy Scientific 
                       Inc 
                       SciFluent Communications 
                       Inc 
                       MedErgy Communications 
                       Inc

As at today's date, Ms. Ralston holds 580,405 ordinary shares of 10p each in the capital of the Company.

There are no further disclosures to be made pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies in respect of the appointment of Ms. Ralston.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOAEASEFESEPFFF

(END) Dow Jones Newswires

October 02, 2018 02:00 ET (06:00 GMT)

Cello Health (LSE:CLL)
Historical Stock Chart
From Jul 2024 to Aug 2024